
Cell proliferation as a biomarker for response to immune checkpoint inhibitors in PD-L1 negative renal cell carcinoma
by Christina Black | Feb 28, 2019

Cell proliferation as a biomarker for response to immune checkpoint inhibitors in highly inflamed renal cell carcinoma (RCC)
by Christina Black | Feb 28, 2019
Follow Us on Twitter
LABCORP EXPANDS ACCESS TO COMPREHENSIVE GENOMIC TESTING THROUGH NEW LUNG CANCER PROGRAM UTILIZING OmniSeq INSIGHT
https://tinyurl.com/59xf82c6
@OmniSeq
@Labcorp
#oncology
#precisionmedicine
Last year, the Buffalo-based cancer diagnostics firm @OmniSeq quietly was acquired by one of the world's largest life science companies, @Labcorp . Developing molecular diagnostic tests for cancer patients, OmniSeq is looking to scale its operations.
https://tinyurl.com/muxryphz